ALG-055009 free base · Synonyms: ALG 055009 · ALG055009
ALG-055009, a thyroid hormone receptor β (THR-β) agonist, exhibits an EC50 of 0.063 μM.
For research use only. Not for human or veterinary use.
ALG-055009 structure
CAS No.: 2542029-03-6
Pack sizes & pricing
| Size | Price | SKU | Stock | |
|---|---|---|---|---|
| 50 mg | USD 597.00 | BP-02271-50mg | In stock | Get quote |
| 100 mg | USD 798.00 | BP-02271-100mg | In stock | Get quote |
| 250 mg | USD 1,683.00 | BP-02271-250mg | In stock | Get quote |
| 500 mg | USD 2,985.00 | BP-02271-500mg | In stock | Get quote |
| 1 g | Inquire | BP-02271-1g | In stock | Inquire |
| 2 g | Inquire | BP-02271-2g | In stock | Inquire |
Need another size or custom synthesis? Request a quote.
Description
ALG-055009, a thyroid hormone receptor β (THR-β) agonist, exhibits an EC50 of 0.063 μM. It has been shown to reduce total cholesterol levels in rats fed a high-fat diet. ALG-055009 is used in the study of fatty liver diseases associated with metabolic dysfunction.
Biological activity
In Vitro ALG-055009 (Compound 14) (1 h) potently activates recombinant human THR-β with an EC50 of 0.063 μM and shows 5.7-fold selectivity for THR-β over recombinant human THR-α in a TR-FRET coactivator biochemical assay. ALG-055009 (18-24 h) activates THR-β in transfected HEK293T cells with an EC50 of 0.050 μM and shows 3.8-fold selectivity for THR-β over THR-α in a luciferase reporter gene assay. ALG-055009 (24 h) induces CPT1A gene expression in Huh-7 liver-derived cells with an EC50 of 9 nM, demonstrating potent on-target activity related to mitochondrial fatty acid β-oxidation. ALG-055009 (1 μM; 0-180 min) shows high metabolic stability in cryopreserved mouse, rat, dog, cynomolgus monkey, and human hepatocytes. ALG-055009 has low CYP450 inhibition potential in human liver microsomes, with an IC50 of 112 μM for CYP2C8, 37 μM for CYP2C9, and IC50 values >50 μM for CYP1A2, CYP2B6, CYP2C19, CYP2D6, and CYP3A4. ALG-055009 (0.07-50 μM; 10 min) weakly inhibits recombinant human UGT1A1 with an IC50 of 37.5 μM, indicating low risk of glucuronidation-related drug-drug interactions. ALG-055009 (5 μM; 1 h) shows good permeability across Caco-2 cell monolayers with an A to B Papp of 2.2 × 10-6 cm/s and a low efflux ratio of 6. ALG-055009 (2 μM; 4 h) shows high plasma protein binding (>96%) in mouse, rat, dog, cynomolgus monkey, and human plasma. ALG-055009 (5 μM; 60 min) has blood-to-plasma ratios of 0.49 to 0.64 in mouse, rat, dog, cynomolgus monkey, and human whole blood, showing no preferential red blood cell partitioning. ALG-055009 is neither a substrate nor an inhibitor (IC50 = 34.4 and 23.8 μM, respectively) of BCRP or OATP1B1. ALG-055009 (up to 10 μM) shows no inhibition of human Nav1.5, Cav1.2, or hERG potassium channels at concentrations up to 10 μM, indicating low cardiovascular safety risk. In Vivo ALG-055009 (Compound 14) (0.015-1.5 mg/kg; p.o.; single dose) produces dose-dependent reductions in serum total cholesterol and LDL-C in high fat diet-fed hypercholesterolemic rats, with a minimum effective dose of 0.075 mg/kg, and induces significant increases in hepatic THR-β target gene expression at doses ≥0.15 mg/kg.
Identifiers
- SMILES
-
O=C1NC(=O)N(N=C1N)C2=CC(Cl)=C(OC3=NNC(=O)C(=C3)C(C)C)C(Cl)=C2 - InChIKey
-
YZZBNKVFMULQCU-UHFFFAOYSA-N
Specifications
- MW (average)
- 425.2260
- Formula
- C16H14Cl2N6O4
- CAS No.
- 2542029-03-6
- Physical state
- Solid
- Color
- Off-white to light yellow
- Shipping
- Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
- Storage
- Powder 4℃, 2 years; In solvent -20℃ 1 month;
Solubility
Soluble in DMSO